详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis: A Meta-Analysis of 8 Randomized Controlled Trials

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Capital Med Univ, Beijing Anzhen Hosp, Dept Epidemiol, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China; [2]Capital Med Univ, Friendship Hosp, Dept Hematol, Beijing, Peoples R China; [3]Baton Rouge Gen Med Ctr, Dept Internal Med, Baton Rouge, LA USA; [4]Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA; [5]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100021, Peoples R China

出处：

DOI：

ISSN：

关键词： coronary artery disease in-stent restenosis drug-eluting balloon drug-eluting stent balloon angioplasty

摘要：

The optimal treatment for in-stent restenosis (ISR) of both bare-metal stent (BMS) and drug-eluting stent (DES) is currently unclear. The aim of this meta-analysis was to assess the role of drug-eluting balloon (DEB) as an optional treatment for ISR. We searched PubMed, MEDLINE, EMBASE, BIOS, and Web of Science from 2005 to July 2014. Eight studies, enrolling 1413 patients were included. Main end points were late lumen loss (LLL), binary in-segment restenosis (BR), major adverse cardiac events (MACEs), target lesion revascularization (TLR), death, myocardial infarction (MI), and stent thrombosis (ST). When compared to plain old balloon angioplasty (POBA), DEB treatment significantly reduced the risk of MACE (risk rato [RR] 0.37, P < .01), death (RR 0.44, P = .04), TLR (RR 0.27, P < .01), BR (RR [95% CI]: 0.23[0.12 to 0.43], P < .01) and associated with better outcomes of LLL ( 0.50 [ 0.65 to 0.35] mm, P < .01). However, the differences were not significant between DEB treatment and DES treatment in all primary and secondary end points. The DEB was a better option to treat ISR when compared to POBA. However, it had similar effects as DES.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 3 区医学

小类 | 4 区外周血管病

最新[2025]版：

大类 | 3 区医学

小类 | 3 区外周血管病

JCR分区：

出版当年[2014]版：

Q2 PERIPHERAL VASCULAR DISEASE

最新[2023]版：

Q2 PERIPHERAL VASCULAR DISEASE

影响因子： 2.6 最新[2023版] 2.6 最新五年平均 2.97 出版当年[2014版] 2.004 出版当年五年平均 2.37 出版前一年[2013版] 2.931 出版后一年[2015版]

第一作者：

第一作者机构： [1]Capital Med Univ, Beijing Anzhen Hosp, Dept Epidemiol, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China;

通讯作者：

通讯机构： [5]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100021, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis. [2]Efficacy of drug-eluting balloon versus sirolimus-eluting stent for the treatment of in-stent restenosis [3]Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease [4]药物洗脱球囊与第二代药物洗脱支架治疗药物支架内再狭窄的观察性研究 [5]Drug-Eluting Balloon Versus Bare-Mental Stent and Drug-Eluting Stent for De Novo Coronary Artery Disease: a Systematic Review and Meta-Analysis [6]Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis [7]Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials [8]A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon Versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis Results From the PEPCAD China ISR Trial [9]Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis [10]药物涂层球囊在冠状动脉小血管病变和支架内再狭窄中的临床应用